iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.
Last trade$84.09
Day change-$0.75 (-0.88%)
Day range$83.85 – $85.12
Volume39,819
Market cap$1.08B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.08B
Price / earnings
45.24×
Price / book
10.19×
Price / sales
12.14×
EV / sales
11.44×
EV / EBITDA
33.48×
Profitability
Earnings per share
$1.88
Return on assets
19.81%
Return on equity
22.53%
Dividend yield
1.5%
Liquidity and leverage
Debt / equity
0×
Current ratio
8.99×
Quick ratio
7.68×
Cash ratio
6.13×
Cash flow
Price / cash flow
39.96×
Price / free cash flow
41.7×
Free cash flow
$26.02M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for IRMD, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$24.2M
$20.47M
$21.98M
$22.69M
$21.2M
$20.41M
$19.51M
$19.39M
Cost of revenue
$5.75M
$5.31M
$5.17M
$5.66M
$4.71M
$4.45M
$4.67M
$4.63M
Gross profit
$18.46M
$15.16M
$16.81M
$17.03M
$16.49M
$15.96M
$14.84M
$14.76M
Selling, general and administrative
$9.44M
$8.11M
$8.62M
$9.14M
$8.99M
$8.29M
$8.79M
$8.39M
Research and development
$875K
$657K
$956K
$799.03K
$674K
$877K
$624K
$570.4K
Total operating expenses
$10.32M
$8.77M
$9.58M
$9.94M
$9.66M
$9.17M
$9.41M
$8.96M
Operating income
$8.14M
$6.39M
$7.24M
$7.09M
$6.83M
$6.79M
$5.43M
$5.8M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
$8.67M
$6.89M
$7.77M
$7.79M
$7.3M
$7.33M
$5.95M
$6.34M
Income taxes
$2.16M
$1.67M
$1.95M
$1.35M
$1.72M
$1.55M
$1.26M
$1.2M
Net income
$6.51M
$5.22M
$5.82M
$6.44M
$5.58M
$5.77M
$4.69M
$5.15M
Net income attributable to common shareholders
$6.51M
$5.22M
$5.82M
$6.44M
$5.58M
$5.77M
$4.69M
$5.15M
EBITDA
$8.55M
$6.8M
$7.69M
$7.47M
$7.22M
$7M
$5.63M
$6M
Basic earnings per share
$0.51
$0.41
$0.46
$0.51
$0.44
$0.45
$0.37
$0.41
Diluted earnings per share
$0.51
$0.41
$0.45
$0.50
$0.43
$0.45
$0.37
$0.40
Recent news
Company coverage with links to the original publishers.
IRadimed reported Q2 2026 revenue of $20.5 million (up 0.5% YoY) with gross margins compressed to 74% from 78% due to manufacturing inefficiencies during the first production ramp of the new 3870 MRI-compatible pump. The company achieved its manufacturing target of 130-135 units and plans to more than double production to over 300 units in Q3. Strong customer demand drove bookings more than double shipments, with 70% of replacements being quad (4-channel) systems at $110,000+ ASP. Management reaffirmed full-year 2026 guidance of $91-96 million revenue and $2.09-2.24 non-GAAP EPS, expecting margin recovery as manufacturing efficiencies improve.
IRADIMED CEO Roger E. Susi sold 7,500 shares indirectly through a trust for approximately $691,000 as part of a systematic Rule 10b5-1 plan. The sale represents routine liquidation rather than a negative signal, with the stock up 60.89% over the past year. The key investment variable is the adoption of the company's new infusion pump, with meaningful data expected by mid-2027.
Iradimed CEO Roger Susi sold 7,500 shares worth ~$694,125 on April 20-21, 2026, as part of a Rule 10b5-1 trading plan adopted in November 2025. The sale is not concerning as it follows a systematic pattern and Susi retains over 4 million shares. Iradimed's strong business performance—with 2025 sales up 14% to $83.8M and net income reaching $22.5M—has driven the stock up 78% over one year, though the elevated forward P/E of 42 suggests waiting for a price dip before buying.
IRADIMED CORPORATION announced its participation in the 38th Annual Roth Conference on March 22 and 24, 2026, at the Ritz-Carlton in Laguna Niguel, CA. CEO Roger Susi and CFO Jack Glenn will host one-on-one meetings with investors. The company is a leader in MRI-compatible medical devices, including its patented MRidium® IV infusion pump system and 3880 patient vital signs monitoring system.
Iradimed Corporation's stock surged 9.26% after reporting its 18th consecutive quarter of record revenue at $22.7 million (up 17% YoY) and beating adjusted net income estimates at $0.54 per share versus $0.48 expected. The medical device maker, which specializes in MRI-compatible infusion pump systems, launched a new product and raised its quarterly dividend from $0.17 to $0.20 per share. The company provided 2026 guidance of $91-96 million in revenue and $2.06-2.21 adjusted net income per share.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Nov 13, 2026
$0.20
Nov 27, 2026
recurring
Aug 14, 2026
$0.20
Aug 28, 2026
recurring
May 15, 2026
$0.20
May 29, 2026
recurring
Feb 23, 2026
$0.20
Mar 6, 2026
recurring
Dec 17, 2025
$0.50
Dec 30, 2025
special
Stock splits
Historical share-structure events and their execution dates.